Improving your health since 2000
Valganciclovir solution is changed into another medicine, ganciclovir, in the body. It may cause severe blood side effects (eg, low platelet levels, low white blood cell counts, anemia). Contact your doctor right away if you develop unusual tiredness or weakness, easy bruising or bleeding, or symptoms of an infection (eg, fever, chills, persistent sore throat).
Valganciclovir solution has caused cancer, birth defects, and a lack of sperm production in animals. Discuss any questions or concerns with your doctor.
Preventing cytomegalovirus (CMV) disease in high-risk kidney and heart transplant patients who are 4 months to 16 years old. It may also be used for other conditions as determined by your doctor.
Valganciclovir solution is an antiviral agent. It works by stopping the growth and reproduction of the virus.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with valganciclovir solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with valganciclovir solution. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if valganciclovir solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use valganciclovir solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use valganciclovir solution.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Seek medical attention right away if any of these SEVERE side effects occur:
Back pain; constipation; cough; diarrhea; dizziness; drowsiness; headache; nausea; stomach pain; trouble sleeping; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in the amount of urine produced; confusion; dark urine; decreased coordination; hallucinations; irregular heartbeat; mental or mood changes (eg, depression); muscle weakness; numbness or tingling of the skin, hands, or feet; seizures; severe or persistent headache, dizziness, or drowsiness; swelling of the arms or legs; symptoms of infection (eg, fever, chills, sore throat); tremors; unsteady movements; unusual bruising or bleeding; unusual tiredness or weakness; vision changes; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blood in the urine; change in the amount of urine produced; dark urine; fever, chills, or sore throat; seizures; severe or persistent diarrhea, vomiting, or stomach pain; tremors; unusual bruising or bleeding; yellowing of the skin or eyes.Proper storage of valganciclovir solution:
Store valganciclovir solution in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Keep the container tightly closed. Throw away any unused medicine after 49 days. Do not use valganciclovir solution if the expiration date on the bottle has passed. Keep valganciclovir solution out of the reach of children and away from pets.
This information should not be used to decide whether or not to take valganciclovir solution or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about valganciclovir solution. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to valganciclovir solution. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using valganciclovir solution.
Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using this medicine.
It is possible that some side effects of valganciclovir may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
Applies to valganciclovir: oral powder for solution, oral tablet
As well as its needed effects, valganciclovir may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking valganciclovir, check with your doctor immediately:More common
Some valganciclovir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
Applies to valganciclovir: oral powder for reconstitution, oral tablet
After oral administration, valganciclovir is rapidly converted to ganciclovir. Therefore, side effects that are known to be associated with ganciclovir administration can be expected to occur with the administration of valganciclovir.
The most common side effects reported in at least one indication by greater than or equal to 20% of patients treated with valganciclovir tablets are diarrhea, pyrexia, nausea, tremor, neutropenia, anemia, graft rejection, thrombocytopenia, and vomiting.[Ref]
Gastrointestinal side effects have included diarrhea (up to 41%), nausea (up to 30%), vomiting (up to 21%), and abdominal pain (up to 15%). Constipation, dyspepsia, abdominal distention, and ascites have been reported.[Ref]
Hematologic side effects have included neutropenia (absolute neutrophil count [ANC] less than 500/mcL: up to 19%; ANC 500 to less than 750/mcL: up to 17%; ANC 750 to less than 1000/mcL: up to 17%), anemia (hemoglobin [Hgb] less than 8 g/dL: up to 8%; Hgb less than 6.5 g/dL: up to 7%; Hgb 6.5 to less than 8 g/dL: up to 13%; Hgb 8 to less than 9.5 g/dL: up to 31%), and thrombocytopenia (less than 25,000 platelets/mcL: up to 4%; 25,000 to less than 50,000 platelets/mcL: up to 6%; 50,000 to less than 100,000 platelets/mcL: up to 22%). Leukopenia, pancytopenia, bone marrow depression, aplastic anemia, and potentially life-threatening bleeding associated with thrombocytopenia have been reported. Neutrophil dysplasia with evidence of bone marrow hypoplasia has also been reported.[Ref]
Immunologic side effects have included graft rejection in transplant patients (up to 24%).[Ref]
Ocular side effects have included retinal detachment (15%).[Ref]
Nervous system side effects have included headache (up to 22%), tremors (up to 28%), insomnia (up to 20%), peripheral neuropathy (9%), and paresthesia (up to 8%). Neurotoxicity, dizziness (excluding vertigo), and convulsions have also been reported.[Ref]
Renal side effects have included elevated serum creatinine (greater than 2.5 mg/dL: up to 17%; greater than 1.5 to 2.5 mg/dL: up to 50%), acute renal failure, renal impairment, dysuria, and decreased creatinine clearance.[Ref]
Oncologic side effects have included the potential to cause cancers; therefore, valganciclovir is considered a potential carcinogen in humans. In animal studies, ganciclovir was found to be carcinogenic.[Ref]
Psychiatric side effects have included psychosis, depression, hallucinations, confusion, and agitation.[Ref]
Other side effects have included pyrexia (up to 31%), catheter-related infections (3%), fatigue, pain, edema, peripheral edema, and weakness. Local and systemic infections, sepsis, pharyngitis/nasopharyngitis, upper respiratory tract infection, urinary tract infection, postoperative wound infection, postoperative complications, postoperative pain, increased wound drainage, and wound dehiscence have been reported.[Ref]
Hypersensitivity side effects have included valganciclovir hypersensitivity.[Ref]
Cardiovascular side effects have included hypertension (up to 18%) and hypotension.[Ref]
Hepatic side effects have included abnormal hepatic function.[Ref]
Metabolic side effects have included hyperkalemia, hypokalemia, hypomagnesemia, hyperglycemia, decreased appetite, dehydration, hypophosphatemia, and hypocalcemia.[Ref]
Musculoskeletal side effects have included back pain, arthralgia, muscle cramps, and limb pain.[Ref]
Respiratory side effects have included cough, dyspnea, rhinorrhea, and pleural effusion.[Ref]
Dermatologic side effects have included dermatitis, pruritus, and acne.[Ref]
1. "Product Information. Valcyte (valganciclovir)" Roche Laboratories, Nutley, NJ.
2. "Oral prodrug of ganciclovir for CMV retinitis." Am J Health Syst Pharm 58 (2001): 946-8
3. Cvetkovic RS, Wellington K "Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients." Drugs 65 (2005): 859-78
4. Segarra-Newnham M, Salazar MI "Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals." Pharmacotherapy 22 (2002): 1124-8
5. Curran M, Noble S "Valganciclovir." Drugs 61 (2001): 1145-50
6. Babel N, Gabdrakhmanova L, Juergensen JS, et al. "Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience." Transplantation 78 (2004): 283-5
7. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK "Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis." Pharmacotherapy 24 (2004): 1323-30
8. Wang TJ, Lin CP, Yang CM, Lin LL "Valgancyclovir as maintenance therapy for cytomegalovirus retinitis in a lung transplant patient-a case report." Transplant Proc 36 (2004): 2826-9
9. Ayala E, Greene J, Sandin R, et al. "Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation." Bone Marrow Transplant 37 (2006): 851-6
10. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. "Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant Recipients." Transplantation 82 (2006): 30-35
11. Molina Perez E, Fernandez Castroagudin J, Seijo Rios S, et al. "Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil." Transplant Proc 41 (2009): 1047-9
12. "Agranulocytosis in kidney transplant recipients receiving tacrolimus, mycophenolate mofetil and valganciclovir." Transplantation 82(1 Suppl 2) (2006): 952
13. Brum S, Nolasco F, Sousa J, et al. "Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil." Transplant Proc 40 (2008): 752-4
14. Humar A, Siegal D, Moussa G, Kumar D "A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients." J Infect Dis 192 (2005): 1154-7
15. Keven K, Basu A, Tan HP, et al. "Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning." Transplant Proc 36 (2004): 3107-12
16. Said T, Nampoory MR, Pacsa AS, et al. "Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients." Transplant Proc 39 (2007): 997-9
17. Taegtmeyer AB, Halil O, Bell AD, Carby M, Cummins D, Banner NR "Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir." Transplantation 80 (2005): 127-30
18. "Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients." Transplantation 82(1 Suppl 2) (2006): 266-7
19. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F "Pharmacokinetics of valganciclovir and ganciclovir in renal impairment." Clin Pharmacol Ther 72 (2002): 142-150
20. Wiltshire H, Paya CV, Pescovitz MD, et al. "Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients." Transplantation 79 (2005): 1477-1483
21. "Efficacy and safety of CMV prophylaxis with valganciclovir 900 mg/day for 100 days versus 450 mg/day for 6 months post-renal transplantation." Transplantation 82(1 Suppl 2) (2006): 585
22. Fellay J, Venetz JP, Aubert JD, Seydoux C, Pascual M, Meylan PR "Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir." Transplant Proc 37 (2005): 949-51
23. Dupuis R, Harris M, Gillis K, et al. "Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients." Transplant Proc 39 (2007): 3266-70
24. Cochrane AB "Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients." Am J Health Syst Pharm 63(19 Suppl 5) (2006): S17-21
25. Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR "Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation." Transplant Proc 39 (2007): 3111-6
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.